{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"description":"Defined as percentage of subjects having a complete response (CR) or partial response (PR) based on investigator assessment per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1).","groups":[{"description":"INCB001158 dosed at 50mg BID in combination with epacadostat (100 mg BID) and pembrolizumab (200 mg Q3W)","id":"OG000","title":"INCB001158 50mg BID+ Epacadostat + Pembrolizumab"},{"description":"INCB001158 dosed at 75mg BID in combination with epacadostat (100 mg BID)and pembrolizumab (200 mg Q3W)","id":"OG001","title":"INCB001158 75 mg BID + Epacadostat + Pembrolizumab"}],"populationDescription":"Data was not collected as no participants were enrolled in Phase 2 of the study","reportingStatus":"POSTED","timeFrame":"Up to approximately 12 months per subject","title":"Phase 2 Only: Objective Response Rate (ORR) of INCB001158 in Combination With Epacadostat ± Pembrolizumab","type":"PRIMARY"}